Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
DALLAS and FORT WORTH, Texas, Nov. 03, 2016 -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing and commercializing innovative extended-release (XR) products for the treatment of attention-deficit/hyperactivity disorder (ADHD), today announced that it will report third quarter 2016 financial results prior to the opening of U.S. financial markets on Thursday, November 10, 2016. Neos management will host a conference call and live audio webcast to discuss results and provide a company update at 8:30 a.m. ET that same day.
The live call may be accessed by dialing (877) 388-8985 for domestic calls, or +1 (562) 912-2654 for international callers, and referencing conference ID number 5573407. A live audio webcast for the conference call will be available on the Investor Relations page of the company’s website at http://investors.neostx.com/.
About Neos Therapeutics
Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified‐release drug delivery technology platforms. Adzenys XR-ODT, indicated for the treatment of ADHD, is the first approved product using the Company’s XR-ODT technology platform. Neos, which is initially focusing on the treatment of ADHD, has two other branded product candidates that are XR medications in ODT or liquid suspension dosage forms. In addition, Neos manufactures and markets its generic equivalent of the branded product Tussionex®1, an XR liquid suspension of hydrocodone and chlorpheniramine indicated for the relief of cough and upper respiratory symptoms of a cold.
1Tussionex® is a registered trademark of the UCB Group of Companies.
Contact: Richard Eisenstadt Chief Financial Officer Neos Therapeutics (972) 408-1389 [email protected] Sarah McCabe Stern Investor Relations, Inc. (212) 362-1200 [email protected]
